Trial Profile
AN OPEN-LABEL STUDY TO EVALUATE THE SAFETY AND PHARMACOKINETICS OF PF-06412528 IN CHILDREN 7-17 YEARS FOR THE TREATMENT OF MODERATE-TO-SEVERE PAIN
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Morphine/naltrexone (Primary)
- Indications Pain
- Focus Pharmacokinetics
- Sponsors Pfizer
- 30 Dec 2019 Status changed from completed to discontinued.
- 25 Jul 2019 Status changed from recruiting to completed.
- 01 Feb 2019 Planned End Date changed from 1 Dec 2019 to 21 Dec 2019.